CTLA-4 blockade appears to broaden blood CD8+ T cell responses against tumor associated antigens, increasing the number of tumor-specificities measured by peptide-MHC multimer staining when pre- and post-blood samples were compared (50). Here, CD8A is linked to neoplasm.